Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

Using 5-α-reductase inhibitors before treatment improves outcomes for patients with metastatic renal cell carcinoma.

Ritlecitinib is the first FDA-approved pill for treating significant hair loss in alopecia areata patients aged 12 and up.

A new treatment plan for hair loss combines targeted therapies and regenerative strategies to stabilize, reverse, and maintain hair growth.

Using regulatory T cells and Rapamycin together improves chronic graft-versus-host disease treatment outcomes in mice.

5-Alpha reductase inhibitors help treat enlarged prostate but may cause sexual side effects.

PROTACs offer a new, precise way to treat cancer by breaking down harmful proteins.

5-Alpha-Reductase inhibitors shorten COVID-19 recovery time in men.

A new method allows for controlled, long-lasting delivery of retinoic acid through the skin with less inflammation.

Blocking the CCR5 receptor may be a new way to treat hair loss from alopecia areata.

A new patch can deliver stable antibodies over time for potential HIV treatment.

Ritlecitinib works well and is safe for treating alopecia areata.

Targeting vitamin D and androgen receptors may effectively treat triple-negative breast cancer, especially with chemotherapy.

Ritlecitinib shows promise for treating alopecia areata, especially with early and extended treatment.

The conclusion suggests that prostate cancer should be classified by castration status and that new therapies targeting androgen receptor signaling show promise.

Therapies targeting the androgen receptor are being developed to treat prostate cancer and improve bone and muscle health.

Adding hormone therapy to radiation improves survival for high-risk prostate cancer recurrence but has side effects.

5-alpha reductase inhibitors, like finasteride and dutasteride, are used for prostate issues, hair loss, and excessive hair growth, may help with COVID-19, but can cause sexual and mental health side effects, and their use in preventing prostate cancer needs more examination.

5-Alpha reductase inhibitors are safe long-term but may be outdated for preventing less significant prostate cancer.

PrEP for HIV is less effective in transgender women mainly due to low adherence to the treatment.

New drugs for rheumatoid arthritis show improvement but have side effects and are not a cure.

Ritlecitinib provides new treatment options for diverse alopecia areata patients.

Clinicians should consider individual factors and communicate risks and benefits when prescribing ritlecitinib for adolescent alopecia areata.

Tenofovir alafenamide fumarate is effective and safer for hepatitis B, with fewer side effects than tenofovir disoproxil fumarate.

Drug repurposing offers promising strategies to improve tuberculosis treatment despite challenges.

Ritlecitinib is generally safe for alopecia areata patients over 72 months.

Adding a second method to PROTACs could improve cancer treatment.

New treatments for male hair loss are being explored to improve effectiveness and reduce side effects.

PROTACs offer new ways to treat hard-to-target diseases, with promising drugs for cancer in advanced trials.

New treatments like JAK inhibitors offer hope for better alopecia areata management.